• 1
    Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Ann Rev Biochem 1986; 55: 69102
  • 2
    Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 12540
  • 3
    Masferrer JL, Isakson PC, Seibert K. Cyclooxygenase-2 inhibitors. a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996; 25: 36372
  • 4
    Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999; 106: 37S42S
  • 5
    Lim HY, Joo HJ, Choi JH et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 51925
  • 6
    Yip-Schneider MT, Barnard DS, Billings SD et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 13946
  • 7
    Mohammed SI, Knapp DW, Bostwick DG et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 564750
  • 8
    Hixson L, Alberts D, Krutzsch M et al. Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994; 3: 4338
  • 9
    Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 37614
  • 10
    Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 49975001
  • 11
    Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 98790
  • 12
    Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55: 42934
  • 13
    Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 820 5
  • 14
    Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 106373
  • 15
    Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 2001; 195: 23643
  • 16
    Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Medical 1983; 172: 2148.
  • 17
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996; 86: 35364
  • 18
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley & Sons, 1997
  • 19
    Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 130611
  • 20
    Marrogi AJ, Travis WD, Welsh JA et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 473944
  • 21
    Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002; 198: 43541
  • 22
    Komhoff M, Guan Y, Shappell HW et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000; 157: 2935
  • 23
    Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S. Expression of cyclooxygenase-2 in patients with bladder cancer. J Urol 2001; 165: 146872
  • 24
    Tanaka F, Otake Y, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer. Cancer Clin Res 2001; 7: 34105
  • 25
    Kumar S, Ghellal A, Li C et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res 1999; 59: 85661
  • 26
    Kim YB, Kim GE, Cho NH et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002; 95: 5319
  • 27
    Ferrandina G, Lauriola L, Zannoni GF et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002; 87: 114552
  • 28
    Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 6325
  • 29
    Ferrandina G, Lauriola L, Zannoni GF et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13: 120511
  • 30
    Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 8617
  • 31
    Achiwa H, Yatabe Y, Hida T et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 10015
  • 32
    Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 52734
  • 33
    Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002; 60: 81621
  • 34
    Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumour invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188 93